Seagen – which is heading for a $43 billion takeover by Pfizer – had also sought to increase damage award on the grounds that Daiichi Sankyo’s infringement of the patent was ‘wilful ...

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing ...

The proceeds from the sale of shares held by Malvinder Singh will go towards part payment of the Rs 3,500-crore arbitral award to ... to Japanese pharma major Daiichi Sankyo.